A
JSPR icon

Abingworth’s Jasper Therapeutics JSPR Stock Holding History

Abingworth’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.72M Hold
562,856
– – 0.89% 9
2022
Q3 		$4.44M Hold
562,856
– – 1.52% 8
2022
Q2 		$10.6M Hold
562,856
– – 3.41% 7
2022
Q1 		$19.5M Hold
562,856
– – 5.54% 5
2021
Q4 		$44.1M Hold
562,856
– – 10.69% 3
2021
Q3 		$58M Buy
+562,856
New +$57.5M 13.17% 3

Other funds holding JSPR

QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIM
Fernwood Investment Management Quincy, Massachusetts $288M AUM 33.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

Abingworth's JSPR Position: Q4 2022 in Review

Abingworth held its Jasper Therapeutics (JSPR) position steady in Q4 2022 at 562,856 shares worth $2.72M. The position accounts for 0.89% of the portfolio, ranked #9.

Abingworth first reported a position in JSPR in Q3 2021 and has held it in 6 quarters since. The position peaked at $58M in Q3 2021. 22 funds tracked by Wall St. Rank hold JSPR as of Q4 2022.

  • Abingworth held 562,856 shares of Jasper Therapeutics worth $2.72M as of Q4 2022.
  • Abingworth left its Jasper Therapeutics share count unchanged in Q4 2022.
  • Jasper Therapeutics made up 0.89% of Abingworth's portfolio in Q4 2022, its #9 holding.
  • Abingworth first reported a position in Jasper Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • Abingworth's Jasper Therapeutics position peaked at $58M in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.